Condition
Hepatopancreaticobiliary (HPB) Malignancy
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07050771Phase 2RecruitingPrimary
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
NCT06631352CompletedPrimary
Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy
NCT04549662Not ApplicableCompletedPrimary
The HepatoPancreaticoBiliary Resection Arginine Immunomodulation (PRIMe) Trial
Showing all 3 trials